Altered gut microbiota composition has been observed in individuals with hidradenitis suppurutiva (HS) and many other inflammatory diseases, including obesity, type 1 and type 2 diabetes. Here, we addressed whether adalimumab, a systemic anti‐inflammatory therapy, may impact the microbiota biochemical profile, particularly on beneficial metabolites such as short‐chain fatty acids (SCFAs). We conducted an observational single‐arm pilot trial to assess gut microbiota composition by 16S rRNA gene sequence analysis and to detect metabolite signatures by gas chromatography in stool samples from participants with HS prior to and 12 weeks after commencing adalimumab therapy. HS individuals that better responded to adalimumab treatment showed a shift in the composition and function of the gut microbiota with significantly increased SCFA acetate and propionate compared to age, gender and BMI‐matched healthy controls. A positive correlation was observed between propionate with Prevotella sp and Faecalibacterium prausnitsii. Increased SCFAs, changes in gut microbiota composition, function and metabolic profile following 12 weeks of adalimumab suggest that targeting SCFAs may be considered a potential biomarker to be evaluated as a complementary protective factor or as a diagnostically relevant signal in HS.
31 December 2022 in British Journal of Dermatology
We performed a systematic review and meta-analysis examining the association between hidradenitis suppurativa (HS) and pilonidal sinus disease (PSD). We found a strong association between HS and PSD, with an increased occurrence of PSD in individuals with HS compared with unaffected controls. Given this strong association, patients with HS should be assessed for PSD.
2 September 2025 in Australasian Journal of Dermatology
Background: Infantile hemangiomas are the most common benign vascular tumours in children. Since the discovery of propranolol for infantile hemangiomas, its increasing side effect profile has prompted research into its beta‐1‐selective counterpart, atenolol. Studies have shown that atenolol is equally effective and more tolerable than propranolol. However, there remains a lack of consensus surrounding atenolol standard dosing and escalation guidelines. Objectives: To retrospectively assess the efficacy and side effects of atenolol used for children with infantile hemangiomas requiring oral beta‐blocker therapy. Methods: A retrospective cohort study at a tertiary dermatology clinic from January 2022 to September 2023 identified infants treated with atenolol for infantile hemangiomas. Infant demographic, lesion characteristics and treatment outcomes were analysed and compared between those who received 1, 1.5 or 2 mg/kg/day of oral atenolol. Results: Of 83 eligible patients, 14.4% ( n = 12) remained on 1 mg/kg/day, 42.2% ( n = 35) received 1.5 mg/kg/day, and 43.4% ( n = 36) increased to 2 mg/kg/day. Overall, 98.8% ( n = 82) responded to atenolol, with 88% ( n = 73) exhibiting a substantial response. Complete involution was associated with earlier age of atenolol commencement ( p = 0.009). Lesions that required escalation to 2 mg/kg/day were more commonly associated with anatomical disfigurement ( p = 0.0121), or were deep, mixed, periorbital, lip or nose infantile hemangiomas. Lesions causing functional impairment were associated with a longer duration of treatment ( p < 0.001). Adverse effects requiring treatment cessation occurred in 3.6% ( n = 3), all being behavioural changes. Conclusions: Atenolol has proven to be an efficacious, safe and tolerable medication for infantile hemangiomas and is a suitable alternative to propanolol. Almost all infants responded to atenolol therapy with more than 50% responding adequately to 1.5 mg/kg/day or less. Infants may be safely commenced on these lower doses with grading up according to response, rather than routinely escalating to 2 mg/kg/day.
Background/Objectives: Pemphigus is a rare blistering disease characterized by a chronic course, associated with significant mortality and morbidity. This review article aims to delve into three Pemphigus subtypes: Pemphigus Vulgaris, Pemphigus Foliaceus and Paraneoplastic Pemphigus, including the safety and efficacy of their treatment options. Methods: A thorough literature search was conducted using PubMed, EMBASE, Medline and Cochrane Library to collate data on pharmaceutical treatments of Pemphigus. Studies were selected based on predefined inclusion criteria, which included English language, peer-reviewed articles published in the date range January 2000 to May 2025. Eligible studies involved adults diagnosed with Pemphigus Vulgaris, Pemphigus Foliaceus or Paraneoplastic Pemphigus who were treated with Glucocorticoids, Mycophenolate mofetil, azathioprine or rituximab. The focus was on identifying adverse effects, complete remission and relapse rates. Results: The analysis revealed that glucocorticoid is the first-line treatment for Pemphigus. However, low remission rates of 34% along with steroid-related adverse effects indicate the use of Mycophenolate and azathioprine as steroid-sparing adjuvant therapies. Emerging treatments with rituximab have demonstrated 90% remission rates, indicating promising results with a comparatively mild side effect profile. Conclusions: The findings highlight the importance of ongoing evaluation of treatment modalities for Pemphigus subtypes to optimise remission rates and minimise adverse effects. Ultimately, studies often fail to isolate specific Pemphigus subtypes owing to the scarcity of literature. There is also a crucial need to address the lack of a standardised grading system for the side effects of glucocorticoids and long-term safety data for rituximab in further longitudinal research.
26 July 2026 in Australasian Journal of Dermatology
Epidermolysis bullosa (EB) is an inherited mechanobullous genodermatosis caused by a mutation in genes encoding proteins integral to skin integrity. Premature termination codon readthrough therapies, such as gentamicin, have promise in facilitating full‐length protein expression in patients with EB. We conducted a systematic review of the effectiveness and adverse effects of gentamicin for wound healing in EB. Six databases were searched to 01 September 2025 for clinical trials investigating gentamicin for EB. Risk of bias was assessed using the ROBINS‐I tool, and data were synthesised descriptively. This study was registered with PROSPERO (CRD42024496582). Five studies involving 24 patients with junctional EB or dystrophic EB were included; four were open‐label and one was double‐blinded. Nineteen of the 24 patients had a known nonsense mutation. Gentamicin was administered topically (two studies), intravenously (two studies) and both topically and intradermally (one study). Wound healing was heterogeneously measured across studies, with all but one showing improved outcomes. All patients demonstrated increased expression of glycoprotein or collagen in skin biopsy specimens after gentamicin treatment. No adverse events were noted. However, four of five studies were at serious risk of bias on ROBINS‐I, primarily owing to lack of blinding and absence of control groups, increasing the risk of bias for subjective outcomes such as wound healing. The available evidence suggests gentamicin may improve wound healing in EB caused by nonsense mutations, but the small number of heterogeneous studies precludes high‐level evidence. Larger, blinded, randomised trials are required to confirm efficacy and long‐term safety.